Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy  by Deneke, M.G. et al.
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imilar  rigidity  but  a  different  biology  (chronic  pancreati-
is  vs  pancreatic  cancer).4,7 At  present  it  can  be  useful  in
ases  with  negative  FNAB  or  as  a  guide  for  directing  FNAB
nto  zones  that  have  a  greater  probability  of  malignancy
hard)  and  avoid  necrotic  tissue  (soft).  It  cannot  yet  replace
US-guided  FNAB.  Further  studies  are  required  that  evalu-
te  and  determine  the  speciﬁc  role  of  EUS  elastography  in
he  evaluation  of  solid  pancreatic  lesions.
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 48-year-old  Caucasian  woman  with  chronic  hepatitis  C
irus  (HCV)  infection,  genotype  4,  presented  to  our  clinic  in
he  summer  of  2011  to  be  evaluated  for  antiviral  treatment.
he  had  evidence  of  portal  hypertension  (splenomegaly,
ow  platelets,  small  esophageal  varices),  cirrhosis  stigmata,
nd  a liver  biopsy  from  2006  had  shown  bridging  ﬁbrosis.
L28B  genotypes  were  subsequently  found  to  be  TT  at
oth  rs12979860  and  rs8099917  loci.  The  patient  had  been
reated  in  2006  with  peginterferon  (peg-IFN)  alpha-2a  with
80  mcg  SQ  weekly  and  ribavirin  (RBV)  1,200  mg/day  for
8  weeks.  Treatment  was  unsuccessful  with  a  complete
arly  virological  response  (EVR)  followed  by  detectable  HCV
NA  at  end-of-treatment  visit,  and  she  was  then  referred  to
ur  center  for  further  evaluation.  In  2008,  she  was  treated
ith  identical  doses  of  peg-IFN/RBV,  achieving  a  complete
VR  (ﬁg.  1).  Due  to  dose-reductions  in  RBV  resulting  from
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Figure  1  Comparison  of  virological  response  to  double  (pegin-
terferon and  ribavirin,  2008)  and  triple  therapy  (plus  telaprevir,
2011) in  a  patient  with  HCV  genotype  4  infection.
anemia  (800  mg/d  on  average),  and  in  light  of  her  prior
breakthrough,  it  was  planned  for  her  to  continue  treatment
for  a  total  of  72  weeks.  Unfortunately,  HCV  RNA  was  positive
around  week  60  (viral  breakthrough)  and  treatment  was
stopped.
The  patient  was  particularly  interested  in  trying  the
direct-acting  antivirals  (DAA),  newly  approved  in  2011.  After
full  disclosure  of  the  lack  of  evidence  on  the  effect  of  DAA
in  genoype  4,  we  agreed  to  try  telaprevir-based  regimen
(TPV).  In  July  2011,  she  was  initiated  on  her  third  course
of  peg-IFN/RBV  (same  doses),  now  with  TPV  (750  mg  every
8  h)  for  the  ﬁrst  12  weeks.  Virological  response  is  shown  in
Figure  1.  There  was  a  3  log10-drop  after  2  weeks  of  treat-
ment  (compared  to  the  1.5  log10-drop  with  the  previous
regimen),  followed  by  complete  EVR  (undetectable  HCV
RNA  at  week  8).  Treatment  was  complicated  by  pancy-
topenia,  requiring  multiple  adjustments  in  peg-IFN  (down
to  135  mcg  SQ  weekly)  and  RBV  (600  mg/day  on  aver-
has  shown  that  TPV  and  BOC  are  effective  inhibitors  of
NS3/4A  isolated  from  genotype  4.3 We  report  a  case  of
successful  treatment  using  a  TPV-containing  regimen  on  a
patient  with  genotype  4  infection,  who  had  previously  failed
treatment  with  peg-IFN/RBV.  A  phase  II  randomized  clinical
trial  showed  effectiveness  of  2  weeks  of  TPV  monother-
apy  in  reducing  HCV  RNA  in  treatment-naive  patients  with
genotype  4.  This  effect  was  much  greater  when  TPV  was
combined  with  peg-IFN/RBV,  and  the  effect  of  triple  therapy
was  greater  than  the  effect  of  peg-IFN/RBV  dual  ther-
apy  (HCV  RNA  reduction  of  -0.77,  -4.32,  and  -1.58  log10
IU/mL,  for  TPV,  TPV+peg-IFN/RBV,  and  peg-IFN/RBV,  respec-
tively).  The  number  of  patients  included  in  this  study  was,
however,  too  small  (n  =  8  per  group)  to  draw  any  conclu-
sions  on  triple  therapy  antiviral  efﬁcacy.4 Remarkably,  there
is  no  published  experience  on  treatment  with  TPV  for
longer  than  two  weeks  in  patients  with  genotype  4.  To  the
best  of  our  knowledge  this  is  the  ﬁrst  reported  case  of  a
treatment-experienced  patient  with  genotype  4  infection
to  achieve  SVR  after  a full-length  TPV-containing  regimen
(12  weeks).  We  believe  this  isolated  clinical  experience
with  a difﬁcult-to-treat  patient  contributes  to  the  limited
knowledge  on  the  effectiveness  of  a TPV-based  antiviral
regimen  on  genotype  4.  Without  a  doubt,  new  DAA  (such
as  the  new  NS5B  polymerase  inhibitor)  will  open  the  door
for  new  antiviral  regimens  with  a  speciﬁc  activity  against
genotype  4.5,6 In  the  meantime,  deﬁning  the  role  of  the
already  approved  DAA  (particularly  TPV)  for  the  treatment
of  HCV  genotype  4,  based  on  well-designed  studies,  should
be  encouraged.
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